Apollomics (APLM) Short term Debt (2023 - 2024)
Apollomics' (APLM) quarterly Short term Debt came in at $3.5 million in Q2 2024, down 17.19% quarter-over-quarter from $4.2 million in Q4 2023.
Analysis
Apollomics (APLM) Short term Debt (2023 - 2024) Analysis & Trends
Apollomics (APLM) has reported Short term Debt for 2 consecutive years, with $3.5 million the latest figure, recorded in Q2 2024.
- On a quarterly basis, Short term Debt changed N/A year-over-year to $3.5 million in Q2 2024; TTM through Jun 2024 was $3.5 million, a N/A change from a year earlier, with the FY2023 full-year figure at $4.2 million, changed N/A from the prior year.
- Short term Debt was $3.5 million for Q2 2024 at Apollomics, down from $4.2 million in the prior quarter.
- Over five years, Short term Debt peaked at $4.2 million in Q4 2023 and troughed at $3.5 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Apollomics | 34.50 Mn | 31.23 Mn | - |